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Objective: The aims of the study reported here were to provide data from six pregnant subjects 
who were enrolled in a clinical trial of antithrombin (AT) concentrate, discuss other published 
case series and case reports, and provide general guidance for the use of AT concentrate for 
inherited AT deficiency in pregnancy.
Methods: In the late 1980s, 31 AT-deficient subjects were enrolled in a prospective treatment 
trial of the plasma-derived AT concentrate Thrombate III®. Herein, newly available treatment 
data about the six pregnant subjects in the trial is tabulated and summarized.
Results: All six experienced venous thromboembolism (VTE) during pregnancy, were dosed 
according to a weight-based protocol, and were treated concomitantly with anticoagulation. 
Loading doses of AT concentrate of 54–62 units/kg were followed by maintenance doses of 
50%–100% of the loading dose for 3–10 days. At the time of labor, loading doses of 46–50 units/kg 
were followed by maintenance doses of 50%–75% of the loading dose for 5–7 days. None of the 
six experienced recurrent thrombosis while receiving treatment with AT concentrate.
Conclusion: Currently we suggest that women with AT deficiency who are pregnant or 
postpartum and have a personal history of VTE or current VTE receive AT concentrates.
Keywords: thrombophilia, thrombosis, plasma-derived concentrate, labor, delivery, heparin.
Introduction
During pregnancy, women have a four- to five-fold increased risk of thromboembolism 
compared with women who are not pregnant.1,2 Eighty percent of thromboembolic 
events in pregnancy are venous,3 with an absolute risk of venous thromboembolism 
(VTE) during pregnancy of between 0.5 and 2.0 per 1000 women.3–9 The most important 
risk factor for VTE in pregnancy is a history of thrombosis. Besides this, the next 
most important risk factor for VTE in pregnancy is thrombophilia.3,10 Thrombophilia 
is present in 20%–50%11–13 of women who experience VTE during pregnancy and the 
postpartum period.
Antithrombin (AT) deficiency was the first inherited thrombophilia to be described in 
1965.14 Since then, multiple reports have documented the association between inherited 
AT deficiency and an increased rate of VTE.15 In pregnancy, the rate is correspondingly 
higher. Historic case series have reported rates of 18%–70%.16–18 The variation in these 
rates can be attributed to the relatively small numbers in each series and to the varied 
definitions of AT deficiency. Although a systematic review including more recent 
studies (some with more liberal thresholds of AT deficiency and not all requiring a 
positive family history) found a lower risk of thrombosis in pregnancy than did the 
initial studies (odds ratio 4.76 [95% confidence interval 2.15, 10.57]); the high rates in 
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the initial studies prompted obstetricians and hematologists 
to recommend full anticoagulation during pregnancy for 
women with AT deficiency.19,20 More recent recommendations 
from the American College of Chest Physicians do not 
endorse anticoagulation unless a woman has had a history 
of thrombosis, but continue to describe AT deficiency as 
a high-risk thrombophilia.21 Despite full anticoagulation 
during pregnancy and the postpartum period, women with AT 
deficiency are still vulnerable to developing VTE, particularly 
at the time of childbirth, when anticoagulation is withheld to 
prevent bleeding complications.
AT is a natural anticoagulant that inactivates thrombin 
by covalently binding to the active serine of thrombin and 
activated factor X (FXa).15 AT can also inactivate other 
coagulation factors, including factors IXa, XIa, and XIIa15 
(Figure 1). AT has a binding site for heparin and, in the 
absence of heparin, has low inhibitory activity against 
thrombin. In contrast, when heparin is present, inhibitory 
activity can be induced at least 1000-fold.22 Importantly, in 
the absence of AT, heparin has little effect.
AT concentrates have been available since 1979.23 Of 
the two AT concentrates currently available, one is purified 
from human plasma (Thrombate III®, Grifols Therapeutics, 
Clayton, NC, USA) and the other is a recombinant product 
produced in transgenic goat mammary glands (ATryn®, GTC 
Biotherapeutics, Framingham, MA, USA). Women with AT 
deficiency may be candidates for AT concentrates during 
pregnancy or the postpartum period when anticoagulation 
is desired, but contraindicated, for example during: invasive 
procedures such as egg retrieval, cerclage, chorionic villus 
sampling, or amniocentesis; miscarriages and ectopic 
pregnancies; episodes of bleeding; surgical procedures; 
neuraxial anesthesia; childbirth, including cesarean 
delivery; postpartum tubal ligation; thrombocytopenia. AT 
concentrates can also be utilized to normalize antithrombin 
levels in women with current thrombosis or recurrent 
thrombosis despite anticoagulation.
AT deficiency is a rare disease affecting between 1 in 
50027 and 1 in 5000 individuals,24 so large trials have not been 
conducted. The clinical trials that were conducted to obtain 
approval for AT concentrates were carried out on patients with 
inherited AT deficiency who were undergoing surgery or giving 
birth. In these small trials,26–28 efficacy was demonstrated by 
the low rate of thrombosis when anticoagulation was withheld 
during the perioperative or peripartum periods. Pregnant 
patients were included in these trials, but details that could 
provide guidance have not been published. The purpose of 
this paper is to provide detailed descriptions from six pregnant 
subjects in one of these trials, discuss the other published case 
series and case reports, and provide general guidance for the use 
of AT concentrates for inherited AT deficiency in pregnancy.
Methods
In the late 1980s, 31 AT-deficient subjects at high risk of 
thrombosis were enrolled in a prospective treatment trial 
of the plasma-derived AT concentrate Thrombate III®.29 
All participating sites had the approval of their respective 
institutional review boards. Of the 31 subjects, six were 
pregnant. Doses were based on the following formula:
  Dose (in units) = (120% minus basal % of normal)
  multiplied by (weight in kg)/(1.4).
Plasma AT levels were generally measured 12 hours 
after the initial dose to ensure that the level remained above 
80%.29 If necessary, a second dose of AT was administered 
at that time. Once predictable peak and trough levels were 
achieved, daily maintenance doses of the AT concentrate were 
administered in the amount of 60% of the loading dose in 
order to maintain plasma AT levels in the range of 70%–120% 
of normal. Although these six cases were mentioned in the 
publication from the original study,26 detailed descriptions 
were not published. Since that time, additional de-identified 
data have been made available by the sponsor. Detailed 
treatment data are provided in Table 1 and the cases are 
summarized in the “Results” section.
For the “Discussion,” a computer-assisted search of 
the SciVerse Scopus electronic database (which includes 
Embase, MEDLINE, and MEDLINE Daily Updates) from 
Intrinsic pathway
(contact activation)
Common
pathway
Extrinsic pathway
(tissue factor)
Tissue factor
(TF)
Antithrombin
Fibrinogen
(Thrombin)
Fibrin
Figure 1 Antithrombin is inhibitory primarily to factors IIa (thrombin) and Xa as 
well as, to a lesser extent, to factors IXa, XIa, XIIa, and VIIa/TF.
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1980 until February 2011 was conducted using different 
combinations of the following keywords: “antithrombin,” 
“ATIII,” “antithrombin deficiency,” “pregnancy,” “clinical 
study,” “prospective study,” “controlled study,” “complica-
tions,” “thrombophilia,” “thrombosis,” and “thrombotic 
complications.”
Results
Case 1
A 17-year-old woman with a strong family history of deep 
vein thrombosis (DVT) was admitted to the hospital at 
20 weeks’ gestation with right leg DVT and pulmonary 
embolism (PE). An emergency inferior vena caval ligation 
was performed and she subsequently received intravenous 
(IV) and, later, subcutaneous (sc) heparin for the duration 
of her pregnancy. She was admitted again at term for 
cesarean delivery. She was treated prophylactically with AT 
concentrate prior to delivery and for 6 days postpartum. The 
delivery and postpartum courses were uneventful, with no 
evidence of thrombosis.
Case 2
An 18-year-old woman was diagnosed with AT deficiency 
following DVT during her first trimester of pregnancy. Her 
plasma AT level was 38% at that time, and it was noted that 
both a brother and sister had histories of AT deficiency. She 
was maintained on sc heparin until admission for labor, 
when she was believed to be preeclamptic and in early 
labor. To raise her AT level, she received four units of fresh 
frozen plasma (FFP), but her plasma AT level remained at 
48%. Therefore, the patient was given a loading dose of AT 
concentrate and was continued on heparin. The next day she 
was started on a maintenance dose of AT concentrate for 
5 days. Her delivery (vaginal) and remaining hospital course 
were uneventful.
Case 3
A 23-year-old woman with a strong family history of AT 
deficiency had been treated with chronic oral anticoagulation 
since 11 years of age. She discontinued warfarin therapy 
because of pregnancy, but 1 month later, in her eighth week 
of pregnancy, was admitted to the hospital with massive 
thrombosis of the left leg. IV heparin treatment over 26 hours 
failed to raise the activated partial thromboplastin time 
(aPTT) above 51.5 seconds. Therefore, AT concentrate was 
administered with a loading dose. A daily maintenance 
course for 3 days was followed by a twice-weekly course 
with sc heparin over 19 days. Despite this regimen, her trough 
plasma AT levels dropped to 50%–60%. Therefore, her AT 
concentrate dose was increased, resulting in trough plasma 
levels generally remaining above 70%. Subsequently, she was 
maintained on the new dose twice weekly with sc heparin 
every 8 hours for the entire duration of the pregnancy as well 
as postpartum, when she was bridged to oral anticoagulant 
therapy. The delivery (vaginal) was uneventful, without 
thrombotic complications.
Case 4
A 27-year-old woman, with known AT deficiency, was 
admitted to the hospital at 12 weeks’ gestation with PE and 
right upper lobe pulmonary infarction. She had a strong 
family history of AT deficiency, with eight maternal aunts 
and uncles with documented AT deficiency, mostly with 
recurrent VTE. The patient was treated with two units 
of FFP and started on IV heparin after receiving a bolus. 
However, heparin treatment caused only transient increases 
in the aPTT, despite administration of another bolus within 
12 hours. Therefore, AT concentrate was initiated with a 
loading dose, which increased the plasma AT level from 50% 
to 110%. The aPTT lengthened to 68 seconds, and subsequent 
measurements demonstrated much less variability than had 
been noted prior to initiating AT concentrate therapy. Within 
3 days, the patient was symptomatically much improved. 
She continued to receive IV heparin and AT concentrate for 
10 days. A maintenance program was begun that consisted 
of sc heparin and AT concentrate twice weekly. Ultimately, 
the aPTT, measured just prior to each AT dose, stabilized 
at .50 seconds and the AT concentrate was discontinued 
41 days after initiation of therapy. After 1 month, AT 
concentrate therapy was resumed once weekly along with sc 
heparin. This regimen was continued until 4 weeks prior to 
delivery, after which the dosing frequency was increased to 
twice weekly. The delivery (vaginal) was uneventful, without 
thrombotic complications.
Case 5
A 28-year-old woman was first treated for bilateral DVT at 
20 years of age. Approximately 6 years later, she became 
pregnant, at which time her warfarin treatment was stopped 
and sc heparin substituted, but she miscarried 1 week later. 
During follow-up, her plasma AT level was found to be as 
low as 18%. She became pregnant again 2 months later and 
was switched from warfarin to sc heparin every 8 hours. 
At approximately 9 weeks’ gestation, she presented with 
a 2-day history of right thigh pain. She was diagnosed as 
having acute DVT, with laboratory parameters indicating 
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Table 1 Details of treatment of six antithrombin (AT)-deficient pregnant patients
Case Age, years Parity Basis for diagnosis Indication for treatment with AT 
during pregnancy
Plasma AT level prior to initial 
AT treatment (%)
Treatment in pregnancy Weeks’ gestation Mode of delivery Summary of procedures or AT 
concentrate for delivery
1 17 0 Strong family history of DVT DVT r leg and PE at 
20 weeks’ gestation
59 IVC ligation, IV and sc heparin Term Cesarean Admitted at full-term for delivery. Given 
50 units/kg loading dose. repeated 72 h later. 
Heparin discontinued and cesarean performed. 
25 units/kg daily × 7 days thereafter. Heparin 
restarted 2 days PP. Coumadin started 4 days 
PP. Nadir AT levels prior to dosing were all 
approximately 80%. Discharged on Coumadin® 
(Bristol-Myers Squibb, New York, NY, USA)
2 18 0 DVT early pregnancy (also 
with strong family history)
DVT early pregnancy 38 at time of diagnosis sc heparin Term Vaginal Admitted in early labor with preeclampsia. 
4 units FFP on admission, AT level still only 48%. 
Given AT 46 units/kg loading dose. Maintenance 
of 34 units/kg × 24 hours then 23 units/kg 
daily × 5 days. AT levels 64%–122%
3 23 0 Strong family history Massive DVT L leg at 
8 weeks’ gestation
50 IV heparin plus AT 54 units/kg loading dose, then 
31 units/kg (60% of loading dose) ×3 days, 
followed by 54 units/kg twice weekly plus sc 
heparin. Then sc heparin plus AT concentrate 
increased to 72–76 units/kg twice weekly to 
maintain nadir plasma AT levels . 70%
Term Vaginal Coumadin PP
4 27 0 Strong family history PE at 12 weeks’ gestation 50 2 units of FFP on admission. IV heparin plus AT 
50 units/kg loading dose, then 33–50 units/kg × 
10 days. Then AT 40–66 units/kg twice weekly 
for 1 more month with sc heparin. Plasma nadir 
AT levels remained . 66%. AT was discontinued 
for 1 month and resumed at 62 units/kg once 
weekly with sc heparin
Term Vaginal AT 62 units/kg increased to twice weekly in the 
4 weeks prior to delivery. Coumadin PP
5 28 0 DVT age 20. Diagnosed after 
miscarriage on Coumadin
DVT r leg 8 weeks’ 
gestation
18 at time of diagnosis FFP on admission. AT level still only 30%–46%. 
AT 62 units/kg loading dose. Daily maintenance 
doses of 38–39 units/kg
9 Termination of 
pregnancy
Discharged on Coumadin
6 35 0 DVT and PE at age 23 and 
strong family history
PE 12 weeks’ gestation 42 IV heparin plus AT 58.5 units/kg daily × 3 days then 
29.3 units/kg × 8 days, then 58.5 units × 1 day
13 Termination of 
pregnancy
Termination of pregnancy after 1 week of 
therapy. Discharged 4 days later on Coumadin
Abbreviations: DVT, deep vein thrombosis; FFP, fresh frozen plasma; IV, intravenous; IVC, inferior vena cava; L, left leg; PE, pulmonary embolism; PP, postpartum; r, right 
leg; sc, subcutaneous.
active disseminated intravascular coagulation. Following 
treatment with FFP, her plasma AT level was only 30%–46%. 
Her heparin therapy was discontinued, she was switched back 
to warfarin, and treatment with AT concentrate was started. 
A loading dose was followed with daily maintenance doses 
for the following 7 days. She then underwent termination 
of pregnancy without incident. Her DVT rapidly improved 
during treatment and she was discharged on warfarin 
anticoagulation.
Case 6
A 35-year-old woman with a history of DVT and PE at 
23 years of age, as well as a family history of thrombosis 
(two sisters, a mother, and aunt had recurrent VTE), was 
admitted with PE at 12 weeks’ gestation. Her plasma AT level 
was 58%. While being treated with heparin, she developed 
recurrent PE and was found to be heparin resistant. IV heparin 
was administered when her plasma AT level was 43% and 
she was continued concomitantly on AT concentrate. She 
received a total of twelve daily infusions of AT concentrate. 
All infusions were well tolerated. Termination of pregnancy 
was performed 1 week after initiation of treatment. She was 
discharged 4 days later on warfarin therapy.
Summary
In this case series, the patients ranged in age from 17 to 
35 years. None had given birth previously. Five of the six 
had a strong family history of AT deficiency and VTE. All 
of these patients developed and were treated for VTE during 
pregnancy. Except for one patient who was diagnosed in the 
current pregnancy and had an AT level of 18%, AT levels at the 
time of initial treatment ranged from 38% to 59%. Besides full 
anticoagulation with IV or sc heparin, four of the six patients 
were treated with plasma-derived AT concentrate at the time of 
diagnosis of VTE, two after receiving FFP. Loading doses of 
AT concentrate of 54–62 units/kg were administered. This was 
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Table 1 Details of treatment of six antithrombin (AT)-deficient pregnant patients
Case Age, years Parity Basis for diagnosis Indication for treatment with AT 
during pregnancy
Plasma AT level prior to initial 
AT treatment (%)
Treatment in pregnancy Weeks’ gestation Mode of delivery Summary of procedures or AT 
concentrate for delivery
1 17 0 Strong family history of DVT DVT r leg and PE at 
20 weeks’ gestation
59 IVC ligation, IV and sc heparin Term Cesarean Admitted at full-term for delivery. Given 
50 units/kg loading dose. repeated 72 h later. 
Heparin discontinued and cesarean performed. 
25 units/kg daily × 7 days thereafter. Heparin 
restarted 2 days PP. Coumadin started 4 days 
PP. Nadir AT levels prior to dosing were all 
approximately 80%. Discharged on Coumadin® 
(Bristol-Myers Squibb, New York, NY, USA)
2 18 0 DVT early pregnancy (also 
with strong family history)
DVT early pregnancy 38 at time of diagnosis sc heparin Term Vaginal Admitted in early labor with preeclampsia. 
4 units FFP on admission, AT level still only 48%. 
Given AT 46 units/kg loading dose. Maintenance 
of 34 units/kg × 24 hours then 23 units/kg 
daily × 5 days. AT levels 64%–122%
3 23 0 Strong family history Massive DVT L leg at 
8 weeks’ gestation
50 IV heparin plus AT 54 units/kg loading dose, then 
31 units/kg (60% of loading dose) ×3 days, 
followed by 54 units/kg twice weekly plus sc 
heparin. Then sc heparin plus AT concentrate 
increased to 72–76 units/kg twice weekly to 
maintain nadir plasma AT levels . 70%
Term Vaginal Coumadin PP
4 27 0 Strong family history PE at 12 weeks’ gestation 50 2 units of FFP on admission. IV heparin plus AT 
50 units/kg loading dose, then 33–50 units/kg × 
10 days. Then AT 40–66 units/kg twice weekly 
for 1 more month with sc heparin. Plasma nadir 
AT levels remained . 66%. AT was discontinued 
for 1 month and resumed at 62 units/kg once 
weekly with sc heparin
Term Vaginal AT 62 units/kg increased to twice weekly in the 
4 weeks prior to delivery. Coumadin PP
5 28 0 DVT age 20. Diagnosed after 
miscarriage on Coumadin
DVT r leg 8 weeks’ 
gestation
18 at time of diagnosis FFP on admission. AT level still only 30%–46%. 
AT 62 units/kg loading dose. Daily maintenance 
doses of 38–39 units/kg
9 Termination of 
pregnancy
Discharged on Coumadin
6 35 0 DVT and PE at age 23 and 
strong family history
PE 12 weeks’ gestation 42 IV heparin plus AT 58.5 units/kg daily × 3 days then 
29.3 units/kg × 8 days, then 58.5 units × 1 day
13 Termination of 
pregnancy
Termination of pregnancy after 1 week of 
therapy. Discharged 4 days later on Coumadin
Abbreviations: DVT, deep vein thrombosis; FFP, fresh frozen plasma; IV, intravenous; IVC, inferior vena cava; L, left leg; PE, pulmonary embolism; PP, postpartum; r, right 
leg; sc, subcutaneous.
followed by a maintenance dose of 50%–100% of the loading 
dose for 3–10 days. Two of the four women who received 
AT concentrate terminated their pregnancies. The other two 
received an extended course with twice-weekly infusions – 
62 units/kg in one case and 72–76 units/kg in the other – to 
maintain trough plasma AT levels . 70%. One patient (who 
did not receive either FFP or AT concentrate) underwent 
inferior vena caval ligation. She and the other remaining 
woman only received AT concentrate at the time of labor, with 
a loading dose of 46–50 units/kg followed by a maintenance 
dose of 50%–75% of the loading dose for 5–7 days. None of 
the women experienced recurrent thrombosis while receiving 
treatment with AT concentrate (Table 1).
Discussion
In this case series of difficult-to-manage AT-deficient 
women with new-onset or recurrent thrombosis during 
pregnancy, plasma-derived AT concentrate was administered 
to normalize AT levels during initial treatment of VTE or 
to provide thromboprophylaxis when anticoagulation was 
withheld at the time of childbirth. AT concentrate was well 
tolerated and none of the women experienced recurrent 
thrombosis while receiving treatment. Loading doses and 
maintenance doses were prescribed according to protocol, 
which succeeded in raising AT levels to $60 IU/dL.
Other studies of pregnant patients with hereditary AT 
deficiency have been published. Two reported on pregnancy 
outcomes in cohorts of women with AT deficiency,32,33 one 
reported on the prevalence of AT deficiency among women 
with pregnancy-related VTE,34 and a number of case series 
and case reports have reported specifically on the course 
and treatment during pregnancy of women with AT defi-
ciency27,28,32–45 (Table 2). Different regimens have been used 
for antepartum and peripartum   thromboprophylaxis. Between 
1981 and 1992, the published regimens for antepartum 
thromboprophylaxis or treatment were for sc heparin or oral 
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anticoagulants.27,32–37 Subsequently, the only anticoagulant 
used alone for antepartum prophylaxis was low-molecular-
weight heparin.42–45 There were two reports from Japan of AT 
concentrate being used for antepartum thromboprophylaxis. 
In two cases it was used alone,38 and in one case it was used 
with heparin.39 In one case, AT concentrate was used in con-
junction with sc heparin for the treatment of VTE.41 In one 
report, no AT concentrate was given at the time of delivery,40 
while, in another report, FFP was given but no AT concen-
trate.37 In five reports, peripartum AT concentrate was given 
just at the time of delivery32,34,36,42,45 and in another five, AT 
concentrate was given for several days surrounding the time 
of delivery.16,27,28,35,43 One study reported the administration 
of AT concentrate for 6 weeks postpartum.44 When doses 
Table 2 Course and treatment during pregnancy of women with antithrombin (AT) deficiency
Pregnancies, 
n
Hx VTE Current 
VTE
Baseline AT 
levels
Antepartum 
prophylaxis
Recurrent 
VTE
Peripartum AT 
concentrate
Brandt32 2 1 – 50%, 65% sc heparin 0 550 units
Hellgren 
et al16
9 2 – 39%–52% sc heparin 1 2000–5000 units (average 
dose 41 units per kg [range 
37–46]) per infusion to 
maintain AT levels of $80%
Michiels 
et al34
2 0 – 42%, 55% Oral anticoagulants 0 3000 units (1 of 2)
Samson 
et al35
1 1 0 20% sc heparin 0 3000 units loading dose 
(50 units per kg); 1500 units 
(25 units per kg) 48 h later, 
then doses adjusted and 
repeated every 48 h to 
maintain AT levels $ 80%
De Stefano36 4 2 1 “Around 50%” sc heparin + oral 
anticoagulants
0 2500–3500 units
Menache 
et al27
5 2 1 29%–65% – 0 5–6 daily infusions of 
30.4 to 93.0 IU/kg
Blondel-Hill 
and Mant37
2 2 0 46%, 62% sc heparin 1 6 units FFP (1 of 2)
Kario et al38 1 1 0 – 3000 units AT concentrate 
3× per week starting at 
34 weeks’ gestation
0
Yamada 
et al39
2 2 0 50%, 59% 6000 units AT concentrate 
(1) and heparin + 
1500 units AT concentrate (1)
1
Grandone 
et al40
15 1/3 
women
– – 0 None
Tiede 
et al28
9 7 0 33%–58% Loading dose 21–81 units 
per kg recombinant AT, 
maintenance infusions of 
160–436 IU/kg/day × 
3–10 days
Hidaka 
et al41
1 1 1 31% sc heparin + 3000 units 
AT concentrate 2–3 × 
per week target $ 70%
1
Sabadell 
et al42
18 5/9 
women
3 (untreated 
pregnancies)
33%–57% 12/18 with LMWH 0 “In labor”
Pamnani 
et al43
1 1 0 54% LMWH 0 3091 units recombinant 
AT followed by 712 units 
per hour
Sharpe 
et al44
1 1 1 38% LMWH + AT concentrate 
2000–3000 units per day 
after sagittal vein 
thrombosis at 34 weeks
3000 units × 3 days at 
delivery then 2000–3000 
units per day × 6 weeks
Kovac et al45 1 1 0 33% LMWH 0 1 dose 50 units per kg
Abbreviations: Hx VTE, medical history of venous thromboembolism; LMWH, low-molecular-weight heparin; VTE, venous thromboembolism; sc, subcutaneous.
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were repeated, they were repeated at varying intervals (eg, 
daily, every 48 hours, two times per week, three times per 
week). When AT concentrate was administered, in twelve 
reports, plasma-derived concentrate was used (n = 47 cases) 
and in two reports recombinant concentrate was used (n = 10 
cases). For plasma-derived AT concentrate, reported doses 
ranged from 550 to 6000 units or were weight-based. In one 
report, loading doses of 50 units/kg were administered, with 
maintenance doses of 25 units/kg every 48 hours. For recom-
binant AT concentrate, loading doses ranged from 21 to 81 
units/kg and maintenance infusions ranged from 160 to 436 
IU/kg/day and were administered for 3–10 days29 or, in one 
case report, 3091 units followed by a maintenance infusion 
of 712 units per hour.43 As for indications, only 29/53 cases 
had a personal history of VTE, with the others diagnosed 
with AT deficiency based on a family history. Fewer (four) 
had current VTE.19,30,31,35,37–39–48
Plasma-derived AT concentrates are well tolerated, 
with minimal adverse reactions, and pose an extremely 
low risk for transmission of infectious agents. (There have 
been no confirmed reports of infectious transmission with 
Thrombate III®). The initial dose is calculated as: initial 
dose = ([desired AT level − current AT level] × weight 
in kg)/1.4. Maintenance doses are then calculated using 
approximately 60% of the loading dose and are given once 
every 24 hours to maintain peak and trough AT activity levels 
in the range of 80% and 120%, respectively.15
With minor glycosylation differences, recombinant AT 
has an identical amino acid structure to endogenous AT. 
Differences in glycosylation, however, do not appear to 
elicit immune reactions. The clinical difference is in the 
mean half-life, which is estimated to be 10.49 ± 7.19 hours 
for recombinant AT, in comparison to 56.8–68.0 hours 
for plasma-derived AT.15 Therefore, recombinant AT is 
administered as a continuous infusion. In a study by 
Tiede et al, the initial dose was calculated as: ([100 − pre-
treatment AT activity level in %] × body weight in kg)/2.28. 
Maintenance infusion (IU/h) is then calculated as: ([100 − pre-
treatment AT activity level in %] × body weight in kg)/10.22.28 
The prescribing information for ATryn provided by GTC 
Biotherapeutics has the loading dose in pregnancy as: 
([100 − baseline AT activity] × body weight in kg)/1.3. 
The maintenance infusion (IU/hr) is: ([100 − baseline AT 
activity] × body weight in kg)/5.4.46
Conclusion
In contrast to the other reports in the literature, the six 
patients discussed here each had a personal history of VTE, 
were dosed according to a weight-based protocol, and were 
treated concomitantly with anticoagulation. Limitations 
of this series are the relatively small number of cases and 
the fact that the cases were treated some time ago with 
anticoagulation regimens that have been replaced by low-
molecular-weight heparin. Despite the fact that the series 
comprises only six cases, this is one of the larger series, 
and, as is true for other rare diseases for which randomized 
trials and even large cohort studies are unavailable, small 
case series or even individual cases can be instructive. 
Otherwise, there are few data and little guidance on the 
management of AT concentrates in pregnancy and at the 
time of delivery. General guidance regarding dosing has been 
provided here. Our current guidance would be that women 
with AT deficiency who are pregnant or postpartum and have 
a personal history of VTE or new-onset or recurrent VTE 
receive AT concentrates. We would suggest that women with 
low levels of AT (,60%) with a compelling family history, 
and those with very low levels of AT (,40%), also receive 
AT concentrates.
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